Y-mAbs Therapeutics, Inc. (YMAB)

NASDAQ: YMAB · IEX Real-Time Price · USD
14.37
-0.26 (-1.78%)
At close: Apr 12, 2024, 4:00 PM
14.08
-0.29 (-2.02%)
After-hours: Apr 12, 2024, 5:04 PM EDT
-1.78%
Market Cap 629.08M
Revenue (ttm) 84.82M
Net Income (ttm) -21.43M
Shares Out 43.78M
EPS (ttm) -0.49
PE Ratio n/a
Forward PE 119.05
Dividend n/a
Ex-Dividend Date n/a
Volume 229,798
Open 14.62
Previous Close 14.63
Day's Range 14.06 - 14.68
52-Week Range 4.60 - 20.90
Beta 0.76
Analysts Buy
Price Target 15.86 (+10.37%)
Earnings Date May 6, 2024

About YMAB

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line r... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 21, 2018
Employees 100
Stock Exchange NASDAQ
Ticker Symbol YMAB
Full Company Profile

Financial Performance

In 2023, YMAB's revenue was $84.82 million, an increase of 29.96% compared to the previous year's $65.27 million. Losses were -$21.43 million, -77.58% less than in 2022.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for YMAB stock is "Buy." The 12-month stock price forecast is $15.86, which is an increase of 10.37% from the latest price.

Price Target
$15.86
(10.37% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer

NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercia...

4 weeks ago - GlobeNewsWire

Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors

Dr. Tagliaferri brings deep biopharmaceutical industry expertise and a successful track record in oncology therapeutic development Dr. Tagliaferri brings deep biopharmaceutical industry expertise and ...

5 weeks ago - GlobeNewsWire

Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments

NEW YORK, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercial...

6 weeks ago - GlobeNewsWire

Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024

NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter and full year...

2 months ago - GlobeNewsWire

Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercial...

3 months ago - GlobeNewsWire

Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index

NEW YORK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercial...

4 months ago - GlobeNewsWire

Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023

NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the third quarter ended S...

5 months ago - GlobeNewsWire

Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director

NEW YORK, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercial...

6 months ago - GlobeNewsWire

Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA

Clearance of CD38-SADA IND marks the second clinical development program utilizing the Company's novel SADA technology platform Clearance of CD38-SADA IND marks the second clinical development program...

6 months ago - GlobeNewsWire

Y-mAbs Announces Publication in Cancers

Naxitamab-based chemo-immunotherapy significantly improves long-term outcomes when administered early during the course of treatment Naxitamab-based chemo-immunotherapy significantly improves long-ter...

6 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Y-mAbs Therapeutics Inc. (NASDAQ: YMAB)

NEW YORK , Sept. 21, 2023 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Y-mAbs Therapeutics Inc. (NASDAQ: YMAB) concerning possible breaches of fiduciary duty.

7 months ago - PRNewsWire

Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology

NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercia...

7 months ago - GlobeNewsWire

Y-mAbs to Participate at Upcoming Investor Conferences in September

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercia...

7 months ago - GlobeNewsWire

Y-mAbs to Participate at Upcoming Investor Conferences

NEW YORK, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercial...

9 months ago - GlobeNewsWire

Y-mAbs to Announce Second Quarter 2023 Financial and Operating Results on August 10, 2023

NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the second quarter ended ...

9 months ago - GlobeNewsWire

Y-mAbs Announces Presentation of Naxitamab Data at ASCO

NEW YORK, May 26, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializ...

11 months ago - GlobeNewsWire

Y-mAbs Announces Presentation of GD2-SADA Study at ASCO

NEW YORK, May 26, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializ...

11 months ago - GlobeNewsWire

Y-mAbs' DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil

NEW YORK, May 23, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializ...

11 months ago - GlobeNewsWire

Y-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial Guidance

NEW YORK, May 08, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializ...

1 year ago - GlobeNewsWire

Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023

NEW YORK, April 28, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended March ...

1 year ago - GlobeNewsWire

Y-mAbs Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments

NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercial...

1 year ago - GlobeNewsWire

Y-mAbs to Announce 2022 Financial and Operating Results on March 30, 2023

NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for year ended December 31, ...

1 year ago - GlobeNewsWire

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Y-mAbs Investors of a Lead Plaintiff Deadline of March 20, 2023

NEW YORK , March 20, 2023 /PRNewswire/ -- Attention Y-mAbs Therapeutics, Inc. ("Y-mAbs") (NASDAQ: YMAB) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced...

1 year ago - PRNewsWire

Y-MABS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Y-mAbs To Contact Him Directly To Discuss Their Options

NEW YORK , March 18, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") ...

1 year ago - PRNewsWire

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (YMAB)

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming March 20, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investor...

1 year ago - Business Wire